Patents by Inventor Sara Caldrer

Sara Caldrer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified effector cell (or chimeric receptor) for treating disialoganglioside G-expressing neoplasia
    Patent number: 10647997
    Abstract: A modified effector cell includes a non-reversibly produced vector-encoded anti-GD2-BB-? chimeric receptor for use in disialoganglioside GD2-expressing neoplasia, which is inserted in the cell, to obtain an effector cell that stably produces the anti-GD2-BB-? chimeric receptor, the chimeric receptor having two distinct mutually fused portions, i.e. an intra-cytoplasmic portion and an extra-cytoplasmic portion.
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: May 12, 2020
    Assignee: St. Jude Children's Research Hospital, Inc.
    Inventors: Massimo Dominici, Sara Caldrer, Maria Carlotta Spano, Paolo Paolucci, Marco Bestagno, Dario Campana
  • Modified Effector Cell (or Chimeric Receptor) for Treating Disialoganglioside GD2-Expressing Neoplasia
    Publication number: 20140302608
    Abstract: A modified effector cell includes a non-reversibly produced vector-encoded anti-GD2-BB-? chimeric receptor for use in disialoganglioside GD2-expressing neoplasia, which is inserted in the cell, to obtain an effector cell that stably produces the anti-GD2-BB-? chimeric receptor, the chimeric receptor having two distinct mutually fused portions, i.e. an intra-cytoplasmic portion and an extra-cytoplasmic portion.
    Type: Application
    Filed: October 25, 2012
    Publication date: October 9, 2014
    Inventors: Massimo Dominici, Sara Caldrer, Maria Carlotta Spano, Paolo Paolucci, Marco Bestagno, Dario Campana